5.29
전일 마감가:
$5.81
열려 있는:
$5.495
하루 거래량:
17.89M
Relative Volume:
0.82
시가총액:
$2.73B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.4129
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-22.09%
1개월 성능:
-29.56%
6개월 성능:
-19.73%
1년 성능:
-46.94%
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
RXRX
Recursion Pharmaceuticals Inc
|
5.29 | 2.73B | 64.60M | -377.75M | -335.64M | -1.55 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
2023-03-16 | 개시 | Needham | Buy |
2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2021-09-21 | 개시 | Berenberg | Buy |
2021-05-11 | 개시 | BofA Securities | Buy |
2021-05-11 | 개시 | Goldman | Neutral |
2021-05-11 | 개시 | JP Morgan | Neutral |
2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Recursion stock hits 52-week low at $5.5 amid market challenges - Investing.com
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks? - The Motley Fool
Recursion Pharmaceuticals CEO sells $836,986 in stock By Investing.com - Investing.com Australia
Recursion Pharmaceuticals CEO sells $836,986 in stock - Investing.com India
Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday? - MSN
Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts (NASDAQ:RXRX) - Seeking Alpha
(RXRX) Investment Report - Stock Traders Daily
Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit? - Insider Monkey
12 Best AI Stocks to Invest in According to Reddit - Insider Monkey
Why Recursion Pharmaceuticals (RXRX) Went Up on Monday? - MSN
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
RXRX Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering - Yahoo Finance
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? - Zacks Investment Research
Recursion Pharmaceuticals Strengthens Board with New Appointments - TipRanks
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun - Yahoo Finance
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Recursion Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Jones Financial Companies Lllp Has $229,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer - Business Wire
Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN
Why Recursion Pharmaceuticals Stock Is Sinking Today - Yahoo Finance
Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus - Insider Monkey
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? - Nasdaq
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga
QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga
Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN
This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN
IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (RXRX) Remains Optimistic Despite Q4 Disappointment - TipRanks
TechBio Latest News - substack.com
How To Trade (RXRX) - Stock Traders Daily
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):